Oppenheimer Holdings, Inc. started coverage on shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) in a report issued on Tuesday morning. The brokerage issued an outperform rating and a $7.00 target price on the biopharmaceutical company’s stock. Oppenheimer Holdings also issued estimates for Sunesis Pharmaceuticals’ Q4 2017 earnings at ($0.33) EPS, FY2017 earnings at ($1.60) EPS, FY2018 earnings at ($0.91) EPS, FY2019 earnings at ($1.01) EPS and FY2020 earnings at ($1.12) EPS.

Several other equities research analysts have also recently weighed in on the stock. UBS AG assumed coverage on shares of Sunesis Pharmaceuticals in a research report on Monday. They issued an outperform rating for the company. Cowen Inc reaffirmed a hold rating on shares of Sunesis Pharmaceuticals in a research report on Thursday, November 2nd. Zacks Investment Research lowered shares of Sunesis Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, October 4th. Cantor Fitzgerald reiterated a hold rating and set a $3.00 price objective on shares of Sunesis Pharmaceuticals in a research note on Wednesday, September 27th. Finally, ValuEngine lowered shares of Sunesis Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The stock has an average rating of Hold and an average target price of $4.17.

Shares of Sunesis Pharmaceuticals (SNSS) opened at $2.91 on Tuesday. Sunesis Pharmaceuticals has a 52-week low of $1.82 and a 52-week high of $4.45. The company has a debt-to-equity ratio of -0.34, a quick ratio of 1.84 and a current ratio of 1.84.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06). During the same period in the previous year, the firm earned ($0.62) EPS. sell-side analysts expect that Sunesis Pharmaceuticals will post -1.58 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Sunesis Pharmaceuticals, Inc. (SNSS) Earns Outperform Rating from Analysts at Oppenheimer Holdings, Inc.” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/24/sunesis-pharmaceuticals-inc-snss-earns-outperform-rating-from-analysts-at-oppenheimer-holdings-inc.html.

In other news, major shareholder Mpm Oncology Impact Management acquired 81,500 shares of Sunesis Pharmaceuticals stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average price of $2.77 per share, for a total transaction of $225,755.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dayton Misfeldt acquired 400,000 shares of Sunesis Pharmaceuticals stock in a transaction that occurred on Friday, October 27th. The shares were purchased at an average price of $2.00 per share, with a total value of $800,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 506,800 shares of company stock valued at $1,091,282. 10.21% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its stake in Sunesis Pharmaceuticals by 77.4% during the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 18,254 shares in the last quarter. Virtu KCG Holdings LLC acquired a new position in Sunesis Pharmaceuticals during the 2nd quarter valued at approximately $208,000. Renaissance Technologies LLC increased its stake in Sunesis Pharmaceuticals by 1.1% during the 1st quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after purchasing an additional 1,230 shares in the last quarter. Sphera Funds Management LTD. increased its stake in Sunesis Pharmaceuticals by 54.6% during the 2nd quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 68,212 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Sunesis Pharmaceuticals by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after purchasing an additional 23,819 shares in the last quarter. Hedge funds and other institutional investors own 39.43% of the company’s stock.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.